It is important to contrast the relative value of identifying common variants that contribute statistically significant, but very modest population attributable risks (the most favorable possible outcome of mega-GWAS) with that of genes that in a subset of families and individuals have high predictive value. Focused studies on individual cases, single families or genetically homogenous populations do not currently attract the same cash or cachet as consortiumbased GWAS studies, but promise greater returns in terms of biological insight and etiological understanding. In conclusion, from a starting point of those studies that have already identified genes that are both explanatory of risk in related individuals and are biologically plausible, a pathway biology approach from these seeds of certainty provides a logical antidote to the uncertainty of ever larger, more heterogenous and more costly GWAS.
NRG1 is a schizophrenia candidate gene which regulates brain development and neural function.
The minor allele of rs7014762 in the NRG1 5 0 core promoter was associated with schizophrenia (P = 0.031), and it significantly predicted reduced NRG1 type III isoform expression in post-mortem human brain of schizophrenia cases (P = 0.001). Our results provide additional evidence for transcriptional dysregulation as a biological mechanism implicating NRG1 in schizophrenia risk.
Association between NRG1 and schizophrenia was originally discovered through haplotype analysis in an Icelandic sample (HAP ICE ) at the 5 0 end of the gene 1 and further replicated in a Scottish population.
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In this report, we examined association between schizophrenia and the NRG1 single nucleotide polymorphism (SNP) rs7014762 because it is situated within a core promoter region 3 and is physically proximal (87 bp) to a functional SNP, which has been shown to influence NRG1 type IV isoform expression. 4 In addition to clinical association analyses, we validated the functional effects of rs7014762 by testing for effects on mRNA expression in postmortem human brain.
Cases (N = 296) and controls (N = 365) were ascertained as part of the Clinical Brain Disorders Branch Sibling Study. The probands met DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria for a broad diagnosis category, including schizophrenia, schizoaffective disorder, psychosis NOS (not otherwise specified), delusional disorder, schizotypal, schizoid or paranoid personality disorder. Control individuals were screened to exclude individuals with psychiatric diagnoses. All participants gave informed consent and self-identified as Caucasian. Blood was collected and DNA was extracted using standard methods. Genotypes were obtained using the Taqman 5 0 -exonuclease allelic discrimination assay.
The post-mortem brain tissue was collected with informed consent from the legal next of kin. The sample was described earlier in detail along with the NRG1 primer and probe sets. 3, 4 Briefly, hippocampi from 84 normal controls (22 females/62 males, 53 African American/25 American Caucasian/5 Hispanic and 1 Asian individual, mean age 40.5±15.4 years (s.d.), post-mortem interval 30.7 ± 13.9 h, pH 6.59 ± 0.32); and 44 schizophrenic patients (15 females/29 males, 24 African Americans/20 Caucasians, mean age 49.7 ± 17.2 years, post-mortem interval 36.3 ± 17.7 h, pH 6.48 ± 0.28) were available for study. Diagnoses were determined by independent reviews of clinical records and family interviews by two psychiatrists using DSM-IV criteria. Macro-and microscopic neuropathological examinations and toxicology screening were performed prior to inclusion. No differences were observed for variables that potentially affect gene expression in human postmortem brain (that is, age, post-mortem interval, pH and RIN, RNA integrity number) by rs7014762 genotype group. NRG1 (types I-IV) mRNA splice isoform expression was measured by real-time quantitative reverse transcriptase-PCR using an ABI Prism 7900 sequence detection system with 384-well format (Applied Biosystems, Foster City, CA, USA).
Case-control analyses used unconditional logistic regression. Effects of rs7014762 on NRG1 isoform mRNA expression were examined using ANOVA (analysis of variance), with genotype and diagnosis as independent factors, controlling for race. Where there was a significant genotype by diagnosis interaction, individual group post hoc tests were examined. P-values were not adjusted for multiple testing.
In cases and controls, rs7014762 was in Hardy Weinberg equilibrium (P > 0.05). The minor allele of rs7014762 showed significant association with schizophrenia case status (minor allele (T) carrier, odds ratio = 1.49 (1.04, 2.15), P-value = 0.031). mRNA expression analysis revealed a significant diagnosis by genotype interaction on type III isoform expression in the hippocampus (F (5, 106) = 5.98; P-value = 0.003). Post hoc analysis showed that the effect of rs7014762 was significant only in patients, whereby individuals heterozygous (LSD, least significant difference; P-value = 0.001) or homozygous (LSD, least significant difference; P-value = 0.002) for the minor allele exhibited significantly lower levels of NRG1 type III expression compared with major allele homozygotes (Figure 1) . No effects of race or race-bygenotype interactions were observed. No effects of genotype were observed for any other NRG1 isoform.
We report association between schizophrenia and rs7014762 in a case-control sample and show that the same allele of rs7014762 in the NRG1 5 0 promoter region significantly predicts lower type III isoform expression levels in patients. NRG1 is expressed throughout the human brain, including the hippocampus and prefrontal cortex, 5 two areas implicated in schizophrenia, and individuals with schizophrenia show abnormalities in ErbB4-NRG1 signaling in the brain when compared with healthy controls. 6 In animal models, NRG1 type III isoform has been associated with axonal myelination, 7 lateral ventricle enlargement, and reduced function in the prefrontal cortex and hippocampus. 8 Disturbances in myelination/oligodendroglial density in individuals with schizophrenia have been observed 9 and suggest that reduced structural connectivity may be part of the neurobiology of schizophrenia. The same allele at this SNP has been shown to be associated with increased risk for bipolar disorder. 10 In addition, rs7014752 is 87 bp from rs6994992 (HAP ICE SNP8NRG1243177) and is in moderate linkage disequilibrium with this HAP ICE SNP (D 0 = 0.96, r 2 = 0.21). SNP rs6994992 has previously been reported to be a functional promoter variant associated with schizophrenia and the regulated expression of a novel brain-specific isoform of NRG1, type IV, in humans, 3, 4 and was associated with alterations in activation in frontal/temporal lobes, higher risk of psychotic symptomology and reduction in premorbid IQ (intelligence quotient) in schizophrenia patients. 11 Together, these observations suggest that variation in the HAP ICE region may impact risk for schizophrenia through transcriptional regulation of multiple NRG1 isoforms. A recent paper in this Journal reported evidence for the involvement of a novel imprinted gene on chromosome 2p12, the leucine-rich repeat transmembrane neuronal 1 (LRRTM1) gene, in the development of schizophrenia/schizoaffective disorder and human handedness. Francks et al.
1 found a three-marker haplotype upstream of LRRTM1 to be associated with schizophrenia when inherited paternally. It is interesting that the same haplotype was also found to be paternally associated with handedness in a sample of reading-disabled sibships, implying the existence of specific imprinting effects on human brain asymmetry. We tested Francks et al.'s hypotheses in large independent samples of (i) schizophrenia and (ii) dyslexia patients with handedness information.
We genotyped the three markers that define the paternally overtransmitted haplotype in the Francks et al. study, rs1446109-rs1007371-rs723524, in 180 parent-offspring trios with schizophrenia. Assuming the hypothesis that true parent-of-origin effects detected in trios should also result in allelic association in case-control studies, 1 we additionally genotyped these markers in 673 patients with schizophrenia (358 males/315 females) and 1060 controls (566 males/494 females). Individuals, who were recruited from consecutive admissions to the Department of Psychiatry at the University of Bonn, Germany, were of German descent, and had given written informed consent to participate in this study. Diagnoses were made according to Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria 2 on the basis of a Structured Clinical Interview for DSM-Disorders (SCID-I) interview, 3 review of medical records and use of the family history method. The Operational Criteria for Psychotic and Affective Illness (OPCRIT) system was also used. 4 Genotyping on DNA samples was carried out using Sequenom's iPlex assay (Sequenom Inc., San Diego, CA, USA), according to the manufacturer's protocol.
Assessment of haplotype frequencies in both, parents of probands and unrelated control samples, showed similar frequencies to those observed by Francks et al. (data not shown), who only tested a two-marker proxy haplotype when they studied association for schizophrenia. In the trio sample, the number of paternally and maternally transmitted haplotypes was estimated using FAMHAP v18. 5 Subsequently, a transmission disequilibrium test was performed. The 2-2-2 haplotype (with '2' representing the minor allele of each single nucleotide polymorphism (SNP)) showed a tendency towards overtransmission for the paternal alleles (12 transmissions (T) vs 6 non-transmissions (NT, Table 1)). However, this tendency did not reach statistical significance (P = 0.153). The complementary 1-1-1-haplotype was observed to be paternally undertransmitted to the affected probands (21 T vs 27 NT). When analysing the case-control sample, no differences in haplotype frequencies between affected and unaffected individuals could be detected.
In order to maximize the power to detect genetic effects at this locus, we combined our and Francks et al.'s family-based samples and conducted a metaanalysis. As shown in Table 1 , the combined analysis revealed a highly significant effect of paternal overtransmission of the 2-X-2 haplotype (P = 0.00097; that is, the proxy haplotype to 2-2-2) and paternal undertransmission of the complementary 1-X-1 haplotype (P = 0.0374; proxy haplotype to 1-1-1).
In addition to the markers forming the specific haplotype upstream of LRRTM1, we genotyped an additional set of 11 tagSNPs to systematically cover variation at this locus (rs13019601, rs1930, rs1446110, rs10170020, rs6718055, rs2862286, rs6712681, rs6733871, rs11126755, rs6755232 and rs767587). We identified the minor allele of rs6733871 to be significantly maternally undertransmitted to affected probands (P = 0.025, Table 1 ). This marker is a non-synonymous SNP (asparagine to serine at position 330). Although this P-value does not withstand correction for multiple testing, additional support for a parentof-origin effect is obtained from the observed tendency of paternal overtransmission for the same allele (21 T vs 14 NT). Hence, we also observe paternal overtransmission/maternal suppression for a coding SNP, which was not analyzed by Francks et al.
Francks et al. further hypothesized that the observed association might be more generally related to human brain asymmetry. They found the three-marker haplotype to be paternally associated with human handedness in a set of reading-disabled sibships. We have access to a
